No Data
No Data
J.P. Morgan Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Announces Target Price $197
Express News | Sarepta Therapeutics Inc : JP Morgan Cuts Target Price to $197 From $202
S&P 500 Futures Climb In Premarket Trading; Target, Fabrinet Lag
Barclays Initiates Sarepta Therapeutics(SRPT.US) With Buy Rating, Announces Target Price $209
High Alpha Stocks That Are Rated 'Overweight' – MS
Piper Sandler Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Maintains Target Price $200
No Data
No Data